Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas.

ABSTRACT: Indolent B-cell non-Hodgkin lymphomas(B-NHL) encompass a heterogeneous category of lymphomas characterized by a wide range of pathological subtypes. With the application of chemoimmunotherapy with rituximab (R-chemo), the prognosis of patients has improved considerably, with a 10-year survival rate of 60-80%. Despite these advancements, a significant number of patients still experience disease progression during or shortly after initial treatment. Those who progress within the first 24 months (POD24) continue to face a notably worse prognosis. This study aims to explore the significance of POD24 in predicting the prognosis of different subtypes of indolent B-cell NHL through a comprehensive literature review. The investigation extends to examining the existing prognostic assessment tools a

SUBMITTER: Li X 

PROVIDER: S-EPMC12031821 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature